- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05294328
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
October 18, 2022 updated by: LENZ Therapeutics, Inc
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Study Overview
Status
Completed
Conditions
Detailed Description
The primary efficacy variable in this INSIGHT study is the percentage of subjects with at least a 3-line improvement.
The secondary efficacy variable is the percentage of subjects who achieve a 2-line or greater improvement from pre-treatment.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Glendale, California, United States, 91204
- INSIGHT-1 Study Site #4
-
-
Indiana
-
Indianapolis, Indiana, United States, 46240
- INSIGHT-1 Study Site #3
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- INSIGHT-1 Study Site #1
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- INSIGHT-1 Study Site #2
-
-
Texas
-
Houston, Texas, United States, 77027
- INSIGHT-1 Study Site #5
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects MUST:
- Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed;
- Be able and willing to follow all instructions and attend study visits;
- Be 45-75 years of age of either sex and any race or ethnicity at Visit 1;
- Have +1.00 to -4.00 diopter (D) of sphere (so that SE results in myopia no more severe than -4.00 SE. See Inclusion 5 below) in both eyes determined by manifest refraction documented at Visit 1;
- Have up to 2.00D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1;
- Be presbyopic as determined at Visit 1
Exclusion Criteria:
Subjects must NOT:
- Be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy;
- Have known contraindications or sensitivity to the use of any of the study medications(s) or their components;
- Have an active ocular infection at Visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;
- Have moderate or severe dry eye determined by total corneal fluorescein staining at Visit 1;
- Have clinically significant abnormal lens findings (e.g., cataract) including early lens changes and/or any evidence of a media opacity in either eye during dilated slit-lamp biomicroscopy and fundus exam documented within 3 months of Visit 1;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination ophthalmic solution (LNZ101) dosed bilaterally
Aceclidine/Brimonidine combination ophthalmic solution
|
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
|
Experimental: Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally
Aceclidine ophthalmic solution
|
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
|
Experimental: Vehicle Ophthalmic Solution dosed bilaterally
Proprietary Vehicle ophthalmic solution
|
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
Ophthalmic Solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With at Least a 3-line Improvement in Near Visual Acuity in the Study Eye
Time Frame: 1 hour
|
The percentage of subjects with at least a 3-line improvement from the pre-dose Aceclidine/Brimonidine (LNZ101) arm versus the vehicle arm, and the Aceclidine arm (LNZ100) versus the vehicle arm.
|
1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Alisyn Facemire, LENZ Therapeutics, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2022
Primary Completion (Actual)
August 22, 2022
Study Completion (Actual)
September 10, 2022
Study Registration Dates
First Submitted
March 4, 2022
First Submitted That Met QC Criteria
March 15, 2022
First Posted (Actual)
March 24, 2022
Study Record Updates
Last Update Posted (Actual)
October 19, 2022
Last Update Submitted That Met QC Criteria
October 18, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Refractive Errors
- Eye Diseases
- Presbyopia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Miotics
- Parasympathomimetics
- Brimonidine Tartrate
- Ophthalmic Solutions
- Pharmaceutical Solutions
- Aceclidine
Other Study ID Numbers
- 21-100-0007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Diseases
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
TBF Genie TissulaireCompletedEnucleated; Eye | Eye CancerFrance
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
Clinical Trials on Aceclidine+Brimonidine combination ophthalmic solution
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncRecruitingEye Diseases | Presbyopia | Miosis | Near VisionChina
-
Alisyn FacemireORA, Inc.CompletedEye Diseases | Refractive Errors | Presbyopia | Miosis | Near VisionUnited States
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
LENZ Therapeutics, IncORA, Inc.CompletedEye Diseases | Presbyopia | Miosis | Near VisionUnited States
-
LENZ Therapeutics, IncORA, Inc.CompletedEye Diseases | Presbyopia | Miosis | Near VisionUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaChina
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleBrazil
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleMexico, Colombia